Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642146 | 0.98 | CYP19A1 (0.46) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7932965 | 0.98 | CYP19A1 (0.46) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7637198 | 0.98 | CYP19A1 (0.46) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7939436 | 0.98 | CYP19A1 (0.46) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7638140 | 0.98 | CYP19A1 (0.46) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7642303 | 0.98 | CYP19A1 (0.46) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7640442 | 0.94 | CYP19A1 (0.41) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7641866 | 0.76 | CYP19A1 (0.43) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7639300 | 0.76 | CYP19A1 (0.43) | CYP19A1TLR4CA1CA2CA4 | |
| SCHEMBL7641527 | 0.74 | CYP19A1 (0.43) | CYP19A1TLR4CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6482966-B2 | REDUCING A CROSSLINK-CYCLIZED CYCLOPENTANONE WITH AN ALKALI METAL HYDRIDE, AND THEN REATING THE RESULTING CROSSLINK-CYCLIZED CYCLOPENTENOL IS WITH A DEHYDRATING AGENT | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-20010012902-A1 | Crosslink-cyclized cyclopentadiene and dihalobis type metal compound containing same as ligand | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| EP-1122229-A1 | Process for the preparation of condensed cyclopentadiene derivatives, 1, 3 disubstituted derivatives and metallocene type compounds containing them as ligand | HONSHU CHEMICAL INDUSTRY CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012902-A1 | Crosslink-cyclized cyclopentadiene and dihalobis type metal compound containing same as ligand | CYC1, DCLRE1A, PPIL1 | CYP19A1 1144/4885TLR4 4259/4885CA1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.